The cellular and molecular processes that control vascular injury responses after
percutaneous coronary intervention involve a complex interplay among vascular cells and …

Although rare, stent thrombosis remains a severe complication after stent implantation owing
to its high morbidity and mortality. Since the introduction of drug-eluting stents (DES), most …

Background Stent thrombosis is a safety concern associated with use of drug-eluting stents.
Little is known about occurrence of stent thrombosis more than 1 year after implantation of …

Objectives: We sought to define the incidence of late clinical events and late stent
thrombosis in patients treated with drug-eluting (DES) versus bare-metal stents (BMS) after …

Background Recent reports have indicated that there may be an increased risk of late stent
thrombosis with the use of drug-eluting stents, as compared with bare-metal stents. Methods …

Background—Although drug-eluting stents (DES) significantly reduce restenosis, they
require 3 to 6 months of thienopyridine therapy to prevent stent thrombosis. The rate and …

Background Numerous studies have compared the outcomes of two competing interventions
for multivessel coronary artery disease: coronary-artery bypass grafting (CABG) and …

Recently investigated applications of polymeric materials for tissue engineering,
regenerative medicine, implants, stents, and medical devices are described in the present …

Objectives: Our purpose was to evaluate the heterogeneity and validity of composite end
points, major adverse cardiac events (MACE) in particular, in cardiology research …

Background—Stent thrombosis (ST) is a serious complication of drug-eluting stent (DES)
implantation regardless of the timing (acute, subacute, or late). The correlates of ST with …